Literature DB >> 28488329

Phosphodiesterase-1b deletion confers depression-like behavioral resistance separate from stress-related effects in mice.

J R Hufgard1, M T Williams1, C V Vorhees1.   

Abstract

Phosphodiesterase-1b (Pde1b) is highly expressed in striatum, dentate gyrus, CA3 and substantia nigra. In a new Floxed Pde1b × CreCMV global knockout (KO) mouse model, we show an immobility-resistance phenotype that recapitulates that found in constitutive Pde1b KO mice. We use this new mouse model to show that the resistance to acute stress-induced depression-like phenotype is not the product of changes in locomotor activity or reactivity to other stressors (learned helplessness, novelty suppressed feeding or dexamethasone suppression), and is not associated with anhedonia using the sucrose preference test. Using tamoxifen inducible Cre, we show that the immobility-resistant phenotype depends on the age of induction. The effect is present when Pde1b is Reduced from conception, P0 or P32, but not if reduced as adults (P60). We also mapped regional brain expression of PDE1B protein and of the Cre driver. These data add to the suggestion that PDE1B may be a target for drug development with therapeutic potential in depression alone or in combination with existing antidepressants.
© 2017 John Wiley & Sons Ltd and International Behavioural and Neural Genetics Society.

Entities:  

Keywords:  Critical period; dentate gyrus; forced swim test; phosphodiesterase-1b; striatum; tail suspension test

Mesh:

Substances:

Year:  2017        PMID: 28488329      PMCID: PMC5677534          DOI: 10.1111/gbb.12391

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  53 in total

Review 1.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

Review 2.  Phosphodiesterase-4 modulation as a potential therapeutic for cognitive loss in pathological and non-pathological aging: possibilities and pitfalls.

Authors:  Rolf T Hansen; Han-Ting Zhang
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 3.  Role of phosphodiesterases in neurological and psychiatric disease.

Authors:  Andrea L O Hebb; Harold A Robertson
Journal:  Curr Opin Pharmacol       Date:  2006-11-20       Impact factor: 5.547

4.  Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues.

Authors:  Viktor Lakics; Eric H Karran; Frank G Boess
Journal:  Neuropharmacology       Date:  2010-05-21       Impact factor: 5.250

5.  Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions.

Authors:  Stephanie Ridder; Sabine Chourbaji; Rainer Hellweg; Alexandre Urani; Christiane Zacher; Wolfgang Schmid; Mathias Zink; Heide Hörtnagl; Herta Flor; Fritz A Henn; Günther Schütz; Peter Gass
Journal:  J Neurosci       Date:  2005-06-29       Impact factor: 6.167

6.  Antidepressant-like effect of etazolate, a cyclic nucleotide phosphodiesterase 4 inhibitor--an approach using rodent behavioral antidepressant tests battery.

Authors:  Ankur Jindal; Radhakrishnan Mahesh; Baldev Gautam; Shvetank Bhatt; Dilip Pandey
Journal:  Eur J Pharmacol       Date:  2012-06-12       Impact factor: 4.432

7.  Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder.

Authors:  Masahiro Fujita; Christina S Hines; Sami S Zoghbi; Alan G Mallinger; Leah P Dickstein; Jeih-San Liow; Yi Zhang; Victor W Pike; Wayne C Drevets; Robert B Innis; Carlos A Zarate
Journal:  Biol Psychiatry       Date:  2012-06-05       Impact factor: 13.382

8.  The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling.

Authors:  J M Bessa; D Ferreira; I Melo; F Marques; J J Cerqueira; J A Palha; O F X Almeida; N Sousa
Journal:  Mol Psychiatry       Date:  2008-11-04       Impact factor: 15.992

9.  Female mice heterozygous for creatine transporter deficiency show moderate cognitive deficits.

Authors:  Emily R Hautman; Amanda N Kokenge; Kenea C Udobi; Michael T Williams; Charles V Vorhees; Matthew R Skelton
Journal:  J Inherit Metab Dis       Date:  2013-05-29       Impact factor: 4.982

10.  Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme.

Authors:  J A Siuciak; S A McCarthy; D S Chapin; T M Reed; C V Vorhees; D R Repaske
Journal:  Neuropharmacology       Date:  2007-04-29       Impact factor: 5.250

View more
  1 in total

1.  Multiple rare inherited variants in a four generation schizophrenia family offer leads for complex mode of disease inheritance.

Authors:  Jibin John; Upasana Bhattacharyya; Navneesh Yadav; Prachi Kukshal; Triptish Bhatia; V L Nimgaonkar; Smita N Deshpande; B K Thelma
Journal:  Schizophr Res       Date:  2019-12-05       Impact factor: 4.939

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.